Varenicline For Smokers In Recovery From Alcohol Dependence
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The goal of this proposal is to explore the potential effectiveness of varenicline to treat
tobacco dependence among recovering alcoholic smokers who, as a group, are at high risk for
tobacco-caused morbidity and mortality. In this open-label phase II clinical trial, we are
proposing to enroll 32 recovering alcoholic smokers who are motivated to stop smoking. After
the initial up titration of varenicline in week 1, all 32 subjects will receive a total of 2
mg/day of varenicline for 12 weeks. In addition to receiving varenicline, all subjects will
receive brief behavioral counseling and our standard intervention at each visit during
participation in the study.